Cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) Infusion Therapy

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is an underdiagnosed, progressive, and fatal disease of the heart muscle. It occurs when transthyretin proteins misfold and form amyloid fibril deposits in the heart walls, causing them to stiffen and leading to restrictive cardiomyopathy and heart failure.

ATTR-CM presents in two forms: hereditary (hATTR-CM), caused by an inherited TTR gene mutation, and wild-type (wtATTR-CM), which occurs with age without an underlying genetic mutation. Symptoms include progressive shortness of breath, fatigue, peripheral edema, arrhythmias, and heart failure symptoms that are often refractory to standard cardiovascular medications.

At Violet Health, we provide advanced therapeutic options and supportive infusion care tailored to patients managing amyloid heart disease. Our clinical team works in close coordination with your cardiologist and heart failure team to ensure safe administration, continuous monitoring, and access to comprehensive patient assistance programs.